KANTAR HEALTH BLOG

kh_blog_hero_1600px
  • Superlative data from NOVA: A Star is Born

    by Stephanie Hawthorne  |  Oct 8, 2016
    Oncology Conference Insight: ESMO 2016 --- Tesaro’s PARP inhibitor, niraparib, has generated a lot of excitement in recent weeks. On September 12, Tesaro announced that it had received an FDA fast track designation for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer.
  • Oncology Conference Insight: ESMO 2016 --- Faslodex® (fulvestrant, AstraZeneca) was approved in 2002 for the treatment of postmenopausal metastatic hormone receptor (HR)-positive breast cancer patients following prior anti-estrogen therapy. To date, utilization of Faslodex has favored second- and third-line settings for this indication, while aromatase inhibitors (AI) are generally favored in the first line for postmenopausal patients.
  • Although short-term financial results from such approach cannot be expected and many of the patient-centric efforts are gestural at this stage, the idea that we should invest our attention in patients in the long term suggests why we have to focus more on patients.
  • Heart disease is the leading cause of death worldwide. According to data from the World Health Organization (WHO), about 17.5 million people die every year due to heart diseases, approximately 31% of all deaths around the globe.
  • Market Access: An Industry Perspective

    by Indira Umareddy  |  Sep 29, 2016
    Almost every pharmaceutical company has a vertical assigned to market access function, and it is widely acknowledged as a critical part of brand planning and commercial success. But ask anyone what market access is and the chances are that you will get diverse answers.